Drugmaker Pfizer is arguing to the state Supreme Court that $8.6 million in punitive damages should not have been awarded in a hormone-replacement therapy case without evidence that its subsidiary misled federal regulators or knew the dangers of the drug were greater than what consumers were warned about.
The Supreme Court granted allocatur in the case of Daniel v. Wyeth Pharmaceuticals Inc. Dec. 5 on one issue: whether punitive damages should have been allowed in a drug products liability case for a drug that was reviewed by the federal Food and Drug Administration. There was no evidence, the defendant says, that it misled the FDA about the risk of the drug by hiding scientific facts and data.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
